Ipratropiumbromid Teva (Ipratropium Bromide Monohydrate)

Ipratropium bromide blocks muscarinic (M3) receptors on airway smooth muscle, preventing acetylcholine‑induced bronchoconstriction. This competitive antagonism relaxes the bronchial muscles, widens the airways, and improves airflow in obstructive respiratory conditions.

The prescribed dose of ipratropium bromide inhalation is determined by the treating physician based on the patient’s clinical condition, severity of disease, and response to therapy. Dosage instructions are provided on the prescription label.

Safety data for ipratropium bromide in pregnancy and lactation are limited. Prescribers should weigh potential benefits against possible risks and consider alternative therapies when appropriate. Women should discuss use with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Ipratropium bromide is an anticholinergic bronchodilator, distinct from β2‑agonists such as albuterol. It provides bronchodilation by blocking muscarinic receptors, whereas β2‑agonists stimulate adrenergic receptors. The two classes are often used together for complementary effects, but ipratropium has a lower risk of tachycardia.

Store the inhalation product at room temperature, below 25 °C. Keep it in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

The medication is delivered via a metered‑dose inhaler or nebulizer as directed by the prescriber. Patients should inhale the dose slowly and hold their breath for a few seconds to maximize pulmonary deposition.

Serious adverse events include paradoxical bronchospasm, severe allergic reactions such as angioedema, and significant urinary retention in susceptible individuals. Patients should seek immediate medical attention if they experience sudden worsening of breathing or signs of an allergic reaction.

Patients with known hypersensitivity to ipratropium bromide or any component of the formulation should avoid the product. It is also contraindicated in individuals with narrow‑angle glaucoma or severe urinary retention unless specifically advised by a healthcare professional.